One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Focal Segmental Glomerulosclerosis (FSGS) Treatment Market

[ 英語タイトル ] Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089038
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 100
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - B. Braun Melsungen AG
- Beckman Coulter Inc. (Danaher)
- Baxter International Inc.
- ChemoCentryx Inc.
- Complexa Inc.
- Dimerix Ltd
- Medtronic PLC
- Pfizer Inc.
- Retrophin Inc.
- Variant Pharmaceuticals Inc.

[Report Description]

The Focal Segmental Glomerulosclerosis (FSGS) Treatment Market is primarily driven by the increasing disease burden, rising focus towards rare diseases, and increasing R&D activity. It has been found that in comparison to other glomerular diseases, the prevalence of FSGS is growing fast worldwide.

As per the NephCure, each year, there are about more than 5,400 patients that are being diagnosed with FSGS and about 20,000 patients with ESRD were earlier affected due to FSGS. In addition, people of African ancestry have five times higher diagnosis rate, and those who do not respond to the steroids move for kidney transplant or dialysis, wherein 30%-40% of patients, the FSGS disease recurs. Further, as per the University of California, the ESRD is increasing by 5% each year. With that, the need for donor's kidneys is rising by 8% each year.

Both developed and emerging markets are going through increasing demand for the kidney transplants and a higher rate of hospitalizations, due to kidney malfunction. This increases the demand to diagnose the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the demand for the FSGS market over the forecast period.

Key Market Trends

Primary FSGS is Expected to Register a High CAGR in the Disease Type Segment

Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually “idiopathic,” referring to rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the major emerging companies having their potential drug candidates in the pipeline are Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals.

Since it is a rare disease, specialty clinical-stage companies are likely to get more funds and are leveraging the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments. Hence, owing to the above-mentioned statements, it has been observed that the segment will have rapid growth over the forecast period.

North America is Expected to Have the Largest Share in the FSGS Treatment Market

North America accounts for a leading share in the market because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. There is an increasing prevalence of FSGS, the presence of state-of-the-art healthcare infrastructure, the high adoption rate of new healthcare technology, and presence of reimbursements are facilitating the market growth.

Moreover, the United States is among the first choice for several manufacturers to conduct clinical trials. Majority of FSGS clinical trials have happened or are in progress in the United States, with high involvement of universities and research centers involved in the funding of the trials, dominated by drugs under trials. For FSGS, several clinical trials and approvals for clinical trials of drugs are under process, which shows a high growth over the forecast period.

Competitive Landscape

The FSGS treatment market is moderately consolidated and consists of the global players that are into the medical devices business that provide products related to dialysis or other diagnostics. The major pharmaceutical companies involved in this market are having their products in the pipeline and are expected to release their products in the coming years.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Focal Segmental Glomerulosclerosis (FSGS)
4.2.2 High Focus on Developing New Treatment Options
4.3 Market Restraints
4.3.1 High Cost of Dialysis and Kidney Transplant
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Disease Type
5.1.1 Primary FSGS
5.1.2 Secondary FSGS
5.2 By Disease Management
5.2.1 Diagnosis Kidney Biopsy Creatinine Test Other Diagnoses
5.2.2 Treatment Drug Therapy Dialysis Kidney Transplant
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Beckman Coulter Inc. (Danaher)
6.1.3 Baxter International Inc.
6.1.4 ChemoCentryx Inc.
6.1.5 Complexa Inc.
6.1.6 Dimerix Ltd
6.1.7 Medtronic PLC
6.1.8 Pfizer Inc.
6.1.9 Retrophin Inc.
6.1.10 Variant Pharmaceuticals Inc.




Recommended reports